A little less than a year after cutting the ribbon at a new glass syringe factory in Hungary, Schott Pharma is making good on its pledge to swiftly expand the site.

Schott—which produces glass vials, syringes, delivery devices and other key packaging products for the pharmaceutical industry—is investing more than 100 million euros ($115 million) at its manufacturing site in Lukácsháza, Hungary, to build a new facility focused on sterile ready-to-use (RTU) cartridges.

The company has already broken ground on the new project, which is expected to add more than 100 new jobs to the site’s current 120-person staff, Schott explained in a Wednesday press release.

RTU cartridges are used to store biologics, including GLP-1s, insulin or hormone therapies for diabetes, obesity and immunological diseases, Schott said.

Though details on the facility buildout were slim in Schott’s release, the packaging expert stressed that it would equip the new cartridge site with the latest in manufacturing tech.

Once up and running, production at the new facility will be “fully integrated and automated with minimal manual intervention,” helping preserve the sterility of Schott’s cartridges, the company added.

The upcoming Lukácsháza site will be the second in Schott’s repertoire to produce sterile cartridges, joining another plant in Switzerland.

Schott announced the investment a little less than a year after opening the doors to its Lukácsháza factory, which came online with an initial 76 million euro investment to help produce prefillable glass syringes.

The Hungarian plant was developed to help Schott further grow its influence in Europe and, at the time of the facility’s debut last year, Schott noted that it was planning “to further invest a multi-million Euro amount in Hungary in prefillable syringes in the next years.”

German packaging and technology specialist Schott created Schott Pharma as a standalone business for its drug packaging unit back in 2022. Schott Pharma flew solo for roughly a year before listing itself as a public company on the Frankfurt Stock Exchange on Sept. 28, 2023.

Reflecting on the move last fall, Schott Pharma CEO Andreas Reisse called the initial public offering a “tremendous success.”